On March 2, 2021 Argobio SAS, a newly-created start-up studio dedicated to life sciences, reported its launch with 50 M€ of committed capital (Press release, Evotec, MAR 2, 2021, View Source;announcements/press-releases/p/argobio-announces-its-launch-with-50-meur-to-create-and-develop-pioneering-biotech-spinouts-with-the-support-of-bpifrance-kurma-partners-angelini-pharma-evotec-and-the-institut-pasteur-6030 [SID1234575898]). Argobio was initiated by Kurma Partners, a leading Paris and Munich-based healthcare venture capital firm, and Bpifrance, the French national investment bank. Kurma and Bpifrance were joined by complementary strategic investors, Angelini Pharma, a private international pharmaceutical company, Evotec, a drug discovery alliance and development partnership company, and the Institut Pasteur, internationally renowned center for biomedical research.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Argobio will create and launch at least five ambitious biotech companies over the next five years sourcing innovative early-stage projects from renowned European academic research institutions. Argobio will focus on selected therapeutic areas, including rare diseases, neurological disorders, oncology, and immunology. It will also look to develop promising platform technologies for therapeutic products. The investors will have the opportunity to invest in the biotech companies created by Argobio.
Argobio will identify, select, and incubate these projects up to company creation, providing broad expertise in the discovery and development of innovative therapeutic products from its team of highly experienced biotech entrepreneurs. The team will be led by Yves Ribeill, Neill Mackenzie and Rémi Soula. Thierry Laugel, Managing Partner at Kurma Partners will be appointed President of Argobio, and Laurent Arthaud, Director of the Biotech and Ecotech investment of Bpifrance, will be appointed Chairman of the Supervisory Board.
"Building on our BRIDGE strategy and partnerships, we continue to be dedicated to making Evotec’s all-modality technology platforms available to validate and accelerate therapeutic concepts from toptier academic institutions globally. As an investor into Argobio, we are delighted to work with a group of distinguished partners and entrepreneurs to build companies committed to the maturation of first-in-class therapeutics towards drugs that which will change patients’ lives and cure diseases with some of the highest medical needs," said Dr. Werner Lanthaler, Chief Executive Officer of Evotec SE.